These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1109 related articles for article (PubMed ID: 9223549)

  • 1. S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: I. Interaction with cloned human (h)5-HT1A, dopamine hD2/hD3 and h alpha2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity.
    Millan MJ; Newman-Tancredi A; Rivet JM; Brocco M; Lacroix P; Audinot V; Cistarelli L; Gobert A
    J Pharmacol Exp Ther; 1997 Jul; 282(1):132-47. PubMed ID: 9223549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
    Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states.
    Millan MJ; Newman-Tancredi A; Audinot V; Cussac D; Lejeune F; Nicolas JP; Cogé F; Galizzi JP; Boutin JA; Rivet JM; Dekeyne A; Gobert A
    Synapse; 2000 Feb; 35(2):79-95. PubMed ID: 10611634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and raclopride.
    Millan MJ; Newman-Tancredi A; Brocco M; Gobert A; Lejeune F; Audinot V; Rivet JM; Schreiber R; Dekeyne A; Spedding M; Nicolas JP; Peglion JL
    J Pharmacol Exp Ther; 1998 Oct; 287(1):167-86. PubMed ID: 9765336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: II. Modulation of hippocampal serotonin release in relation to potential anxiolytic properties.
    Millan MJ; Hjorth S; Samanin R; Schreiber R; Jaffard R; De Ladonchamps B; Veiga S; Goument B; Peglion JL; Spedding M; Brocco M
    J Pharmacol Exp Ther; 1997 Jul; 282(1):148-61. PubMed ID: 9223550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of dialysate levels of dopamine, noradrenaline, and serotonin (5-HT) in the frontal cortex of freely-moving rats by (-)-pindolol alone and in association with 5-HT reuptake inhibitors: comparative roles of beta-adrenergic, 5-HT1A, and 5-HT1B receptors.
    Gobert A; Millan MJ
    Neuropsychopharmacology; 1999 Aug; 21(2):268-84. PubMed ID: 10432475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat.
    Gobert A; Rivet JM; Lejeune F; Newman-Tancredi A; Adhumeau-Auclair A; Nicolas JP; Cistarelli L; Melon C; Millan MJ
    Synapse; 2000 Jun; 36(3):205-21. PubMed ID: 10819900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel benzodioxopiperazines acting as antagonists at postsynaptic 5-HT1A receptors and as agonists at 5-HT1A autoreceptors: a comparative pharmacological characterization with proposed 5-HT1A antagonists.
    Millan MJ; Canton H; Gobert A; Lejeune F; Rivet JM; Bervoets K; Brocco M; Widdowson P; Mennini T; Audinot V
    J Pharmacol Exp Ther; 1994 Jan; 268(1):337-52. PubMed ID: 8301575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile.
    Millan MJ; Gobert A; Newman-Tancredi A; Lejeune F; Cussac D; Rivet JM; Audinot V; Adhumeau A; Brocco M; Nicolas JP; Boutin JA; Despaux N; Peglion JL
    J Pharmacol Exp Ther; 2000 Jan; 292(1):38-53. PubMed ID: 10604930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The serotonin1A receptor partial agonist S15535 [4-(benzodioxan-5-yl)1-(indan-2-yl)piperazine] enhances cholinergic transmission and cognitive function in rodents: a combined neurochemical and behavioral analysis.
    Millan MJ; Gobert A; Roux S; Porsolt R; Meneses A; Carli M; Di Cara B; Jaffard R; Rivet JM; Lestage P; Mocaer E; Peglion JL; Dekeyne A
    J Pharmacol Exp Ther; 2004 Oct; 311(1):190-203. PubMed ID: 15146031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of the activity of central serotoninergic neurons by novel serotonin1A receptor agonists and antagonists: a comparison to adrenergic and dopaminergic neurons in rats.
    Gobert A; Lejeune F; Rivet JM; Audinot V; Newman-Tancredi A; Millan MJ
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1032-46. PubMed ID: 7791073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha2-adrenergic receptor blockade markedly potentiates duloxetine- and fluoxetine-induced increases in noradrenaline, dopamine, and serotonin levels in the frontal cortex of freely moving rats.
    Gobert A; Rivet JM; Cistarelli L; Melon C; Millan MJ
    J Neurochem; 1997 Dec; 69(6):2616-9. PubMed ID: 9375697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantification and pharmacological characterization of dialysate levels of noradrenaline in the striatum of freely-moving rats: release from adrenergic terminals and modulation by alpha2-autoreceptors.
    Gobert A; Billiras R; Cistarelli L; Millan MJ
    J Neurosci Methods; 2004 Dec; 140(1-2):141-52. PubMed ID: 15589344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain.
    Assié MB; Ravailhe V; Faucillon V; Newman-Tancredi A
    J Pharmacol Exp Ther; 2005 Oct; 315(1):265-72. PubMed ID: 15987834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postsynaptic 5-HT(1A) receptors mediate an increase in locomotor activity in the monoamine-depleted rat.
    Mignon L; Wolf WA
    Psychopharmacology (Berl); 2002 Aug; 163(1):85-94. PubMed ID: 12185404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
    Glennon JC; Van Scharrenburg G; Ronken E; Hesselink MB; Reinders JH; Van Der Neut M; Long SK; Feenstra RW; McCreary AC
    Synapse; 2006 Dec; 60(8):599-608. PubMed ID: 17001660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of burst firing in ventral tegmental area dopaminergic neurons by activation of serotonin (5-HT)1A receptors: WAY 100,635-reversible actions of the highly selective ligands, flesinoxan and S 15535.
    Lejeune F; Millan MJ
    Synapse; 1998 Oct; 30(2):172-80. PubMed ID: 9723787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the aminomethylchroman derivative BAY x 3702 as a highly potent 5-hydroxytryptamine1A receptor agonist.
    De Vry J; Schohe-Loop R; Heine HG; Greuel JM; Mauler F; Schmidt B; Sommermeyer H; Glaser T
    J Pharmacol Exp Ther; 1998 Mar; 284(3):1082-94. PubMed ID: 9495870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: I. Cellular, electrophysiological, and neurochemical profile in comparison with ropinirole.
    Millan MJ; Cussac D; Gobert A; Lejeune F; Rivet JM; Mannoury La Cour C; Newman-Tancredi A; Peglion JL
    J Pharmacol Exp Ther; 2004 Jun; 309(3):903-20. PubMed ID: 14978194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. S18616, a highly potent spiroimidazoline agonist at alpha(2)-adrenoceptors: II. Influence on monoaminergic transmission, motor function, and anxiety in comparison with dexmedetomidine and clonidine.
    Millan MJ; Lejeune F; Gobert A; Brocco M; Auclair A; Bosc C; Rivet JM; Lacoste JM; Cordi A; Dekeyne A
    J Pharmacol Exp Ther; 2000 Dec; 295(3):1206-22. PubMed ID: 11082458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.